Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 52: EUROPA-Studie - Perindopril - Benefit Abb. 53: EUROPA-Studie - Interaktionsanalyse Abb. 54: EUROPA-Studie - Benefits Aktuelles Bild - Abb. 55: EUROPA-Studie - HOPE-Studie Abb. 56: EUROPA-Studie - HOPE-Studie Abb. 57: EUROPA-Studie - HOPE-Studie Abb. 58: EUROPA-Studie - Ergebnisse Zum letzten Bild
Abbildung 55: EUROPA-Studie - HOPE-Studie
EUROPA study with perindopril 8 mg once daily extends the observations of HOPE, in which cardiovascular events were reduced with ACE inhibition in high-risk patients with coronary heart disease. The risk of patients in EUROPA was lower than in HOPE, which selected older patients (66 vs 60), who had higher percentage of cardiovascular risk disease PVD, hypertension), stroke or diabetes.
 
EUROPA-Studie - HOPE-Studie
Vorheriges Bild Nächstes Bild   


Abbildung 55: EUROPA-Studie - HOPE-Studie
EUROPA study with perindopril 8 mg once daily extends the observations of HOPE, in which cardiovascular events were reduced with ACE inhibition in high-risk patients with coronary heart disease. The risk of patients in EUROPA was lower than in HOPE, which selected older patients (66 vs 60), who had higher percentage of cardiovascular risk disease PVD, hypertension), stroke or diabetes.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung